These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31803734)

  • 21. Hub gene identification and prognostic model construction for isocitrate dehydrogenase mutation in glioma.
    Jia Y; Yang W; Tang B; Feng Q; Dong Z
    Transl Oncol; 2021 Jan; 14(1):100979. PubMed ID: 33290989
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA copy number analysis of Grade II-III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status.
    Cohen A; Sato M; Aldape K; Mason CC; Alfaro-Munoz K; Heathcock L; South ST; Abegglen LM; Schiffman JD; Colman H
    Acta Neuropathol Commun; 2015 Jun; 3():34. PubMed ID: 26091668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study.
    Bisdas S; Shen H; Thust S; Katsaros V; Stranjalis G; Boskos C; Brandner S; Zhang J
    Sci Rep; 2018 Apr; 8(1):6108. PubMed ID: 29666413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.
    Wu CC; Jain R; Radmanesh A; Poisson LM; Guo WY; Zagzag D; Snuderl M; Placantonakis DG; Golfinos J; Chi AS
    AJNR Am J Neuroradiol; 2018 Oct; 39(10):1814-1820. PubMed ID: 30190259
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulator dysfunction and oncogene activation in IDH mutant gliomas.
    Flavahan WA; Drier Y; Liau BB; Gillespie SM; Venteicher AS; Stemmer-Rachamimov AO; Suvà ML; Bernstein BE
    Nature; 2016 Jan; 529(7584):110-4. PubMed ID: 26700815
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue 2-Hydroxyglutarate as a Biomarker for
    Sim HW; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX
    Clin Cancer Res; 2019 Jun; 25(11):3366-3373. PubMed ID: 30777876
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
    Chen R; Cohen AL; Colman H
    Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isocitrate dehydrogenase 1 Gene Mutation Is Associated with Prognosis in Clinical Low-Grade Gliomas.
    Li MY; Wang YY; Cai JQ; Zhang CB; Wang KY; Cheng W; Liu YW; Zhang W; Jiang T
    PLoS One; 2015; 10(6):e0130872. PubMed ID: 26115094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Machine Learning-Based Radiomics for Molecular Subtyping of Gliomas.
    Lu CF; Hsu FT; Hsieh KL; Kao YJ; Cheng SJ; Hsu JB; Tsai PH; Chen RJ; Huang CC; Yen Y; Chen CY
    Clin Cancer Res; 2018 Sep; 24(18):4429-4436. PubMed ID: 29789422
    [No Abstract]   [Full Text] [Related]  

  • 32. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Financially effective test algorithm to identify an aggressive, EGFR-amplified variant of IDH-wildtype, lower-grade diffuse glioma.
    Bale TA; Jordan JT; Rapalino O; Ramamurthy N; Jessop N; DeWitt JC; Nardi V; Alvarez MM; Frosch M; Batchelor TT; Louis DN; Iafrate AJ; Cahill DP; Lennerz JK
    Neuro Oncol; 2019 May; 21(5):596-605. PubMed ID: 30496526
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
    Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
    Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.
    Shirahata M; Ono T; Stichel D; Schrimpf D; Reuss DE; Sahm F; Koelsche C; Wefers A; Reinhardt A; Huang K; Sievers P; Shimizu H; Nanjo H; Kobayashi Y; Miyake Y; Suzuki T; Adachi JI; Mishima K; Sasaki A; Nishikawa R; Bewerunge-Hudler M; Ryzhova M; Absalyamova O; Golanov A; Sinn P; Platten M; Jungk C; Winkler F; Wick A; Hänggi D; Unterberg A; Pfister SM; Jones DTW; van den Bent M; Hegi M; French P; Baumert BG; Stupp R; Gorlia T; Weller M; Capper D; Korshunov A; Herold-Mende C; Wick W; Louis DN; von Deimling A
    Acta Neuropathol; 2018 Jul; 136(1):153-166. PubMed ID: 29687258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isocitrate dehydrogenase1 mutation reduces the pericyte coverage of microvessels in astrocytic tumours.
    Sun C; Zhao Y; Shi J; Zhang J; Yuan Y; Gu Y; Zhang F; Gao X; Wang C; Wang Y; Wang Z; Hu P; Qin J; Xiao L; Chang T; Wang L; Xi Y; Yin H; Chen H; Zhang L; Cheng G; Lin J; Zhang M; Li Z; Ye J
    J Neurooncol; 2019 Jun; 143(2):187-196. PubMed ID: 31004262
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival Risk Prediction Models of Gliomas Based on IDH and 1p/19q.
    Zou H; Li C; Wanggou S; Li X
    J Cancer; 2020; 11(15):4297-4307. PubMed ID: 32489448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI.
    Aliotta E; Nourzadeh H; Batchala PP; Schiff D; Lopes MB; Druzgal JT; Mukherjee S; Patel SH
    AJNR Am J Neuroradiol; 2019 Sep; 40(9):1458-1463. PubMed ID: 31413006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas.
    Macaulay RJ
    Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.